Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Motzer R.J.,,"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma",2006,Journal of Clinical Oncology,1445,10.1200/JCO.2005.02.2574,United States,Article,New York,0,Journal,2-s2.0-33644833910
Cohen H.T.,,Renal-cell carcinoma,2005,New England Journal of Medicine,1160,10.1056/NEJMra043172,United States,Review,Boston,0,Journal,2-s2.0-28844484134
Krause D.,,Tyrosine kinases as targets for cancer therapy,2005,New England Journal of Medicine,1063,10.1056/NEJMra044389,United States,Review,Boston,0,Journal,2-s2.0-22044442973
Atkins M.B.,,Innovations and challenges in renal cancer: Consensus statement from the first international conference,2004,Clinical Cancer Research,35,10.1158/1078-0432.CCR-040720,United States,Conference Paper,Boston,1,Journal,2-s2.0-4644303268
Yang J.,,"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer",2003,New England Journal of Medicine,2420,10.1056/NEJMoa021491,United States;United States,Article,Bethesda;Bethesda,0,Journal,2-s2.0-0042343801
Bergers G.,,Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,2003,Journal of Clinical Investigation,1177,10.1172/JCI200317929,United States;United States,Article,San Francisco;San Francisco,1,Journal,2-s2.0-0038476608
Sun L.,,"Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase",2003,Journal of Medicinal Chemistry,438,10.1021/jm0204183,United States,Article,San Francisco,0,Journal,2-s2.0-0037468875
Mendel D.,,"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship",2003,Clinical Cancer Research,1730,,United States,Article,San Francisco,0,Journal,2-s2.0-12244301581
Demetri G.D.,,Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).,2002,"European journal of cancer (Oxford, England : 1990)",111,10.1016/s0959-8049(02)80603-7,United States,Review,Boston,0,Journal,2-s2.0-0036770178
